logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
CMPS
COMPASS Pathways plc
13.51
2 x 9.84
2 x 17.31
bid
ask
-
0.22
1.60%
2 @ 06:54 AM
13.33 -0.18 (1.33%)
Ytd95.80%
1y205.66%
13.43
day range
13.94
4.40
52 week range
15.40
Open13.65Prev Close13.73Low13.43High13.94Mkt Cap1.87B
Vol1.77MAvg Vol3.61MEPS-3.79P/EN/AForward P/E-9.43
Beta2.50Short Ratio3.99Inst. Own68.00%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0350-d Avg13.07200-d Avg8.971yr Est23.75

CMPS News

Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization
seekingalpha.com
Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commer

Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside

Compass Pathways: Still A Buy, But The Exit Just Got Complicated
seekingalpha.com
Compass Pathways: Still A Buy, But The Exit Just Got Complicated

COMPASS Pathways remains a Buy, but Eli Lilly's acquisition of AtaiBeckley narrows CMPS's long-term

10 Health Care Stocks With Whale Alerts In Today’s Session
benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w
benzinga.com
HC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $65

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Compass Pathways (NASDAQ:CMPS) with
benzinga.com
Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $18

Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight a
benzinga.com
RBC Capital Maintains Outperform on Compass Pathways, Lowers Price Target to $21

RBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform an
benzinga.com
B. Riley Securities Maintains Buy on Compass Pathways, Raises Price Target to $22

B. Riley Securities analyst Madison El-Saadi maintains Compass Pathways (NASDAQ:CMPS) with a Buy

benzinga.com
Compass Pathways Collaborates With U.S. Department Of Veterans Affairs On A Multi-Site Randomized Co

The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-
benzinga.com
UPDATE: Compass Pathways Q2 Adj. EPS $(0.36) Beats $(0.40) Estimate. (Adj EPS excludes Fair value ch

Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.36) per share which beat the analyst
benzinga.com
Compass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate

Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(1.88) per share which missed the analy